In the ICON7 trial evaluating bevacizumab in ovarian cancer, in which patient subgroup was the GREATEST overall survival benefit demonstrated?
- A Stage I/II completely resected disease
- B High-risk disease: Stage III with > 1 cm residual or Stage IV ✓
- C Stage III with optimal debulking
- D BRCA1/2 mutated patients regardless of stage
Correct answer: B. High-risk disease: Stage III with > 1 cm residual or Stage IV
Explanation
The ICON7 trial showed that adding bevacizumab to carboplatin-paclitaxel followed by maintenance bevacizumab provided the greatest overall survival benefit in women with high-risk disease — specifically Stage III with > 1 cm residual disease or Stage IV ovarian cancer. In the overall population, progression-free survival improved but overall survival was similar. The high-risk subgroup showed a clinically meaningful survival advantage of approximately 5 months.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.